Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, U...
Guardado en:
Autores principales: | Green J, Karen K, Cox ME |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/26c4615e0a4c4f67a75f4a2111c8b728 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010) -
The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh CJ, et al.
Publicado: (2014) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Karen Barnard, et al.
Publicado: (2010) -
Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial
por: Zhang F, et al.
Publicado: (2021) -
Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)